Bone Biologics Corporation
2 Burlington Woods Drive, Suite 100
Burlington, MA 01803
January 22, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jane Park
| Re: | Bone Biologics Corporation Registration Statement on Form S-3 File No. 333-276412 |
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Bone Biologics Corporation, a Delaware corporation (the “Registrant”), hereby requests that the effectiveness of the registration statement on Form S-3 (File No. 333-276412), initially filed with the U.S. Securities and Exchange Commission on January 5, 2024, as amended by the Pre-Effective Amendment No. 1 filed on January 17, 2024, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time on January 24, 2024 or as soon thereafter as practicable.
If you have any questions or comments, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.
| Very truly yours, | ||
| Bone Biologics Corporation | ||
| By: | /s/ Jeffrey Frelick | |
| Jeffrey Frelick | ||
| President and Chief Executive Officer | ||
